Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • feixiang1019
    Junior Member
    • Mar 2023
    • 3

    #1

    Wield MiSeq error rate at the beginning

    Recently when we run amplicon libraries on MiSeqs(2 miSeq instruments), we got wield high error rate dots at the beginning of each read. The overall error rate and Q30 was good, we just would like to understand why this was happening. Did anyonce face this before?

    Thanks
  • Ben3
    Member
    • Sep 2022
    • 79

    #2
    feixiang1019 that's very strange. Have you experienced this with any other libraries you have run?

    Also, what are the amplicons you are sequencing? Is there a lot of diversity in the sequences?

    Comment

    • JBKri
      Member
      • Jan 2014
      • 80

      #3
      We see this all the time with amplicon libraries with low nucleotide diversities. I had the impression this is unavoidable with low diversity libraries.

      Comment

      • Ben3
        Member
        • Sep 2022
        • 79

        #4
        JBKri that's what I was expecting. I haven't run amplicons on an Illumina instrument in a while, but I always remember steep drop-offs when there was low diversity.

        feixiang1019 if this remains an issue you can add more PhiX to your runs or add in more diverse samples.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
          by SEQadmin2



          CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

          Despite this, “CRISPR helped turn genome editing from a specialized technique into
          ...
          07-31-2026, 11:01 AM
        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 08-03-2026, 10:13 AM
        0 responses
        21 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-31-2026, 02:55 AM
        0 responses
        35 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        25 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        21 views
        0 reactions
        Last Post SEQadmin2  
        Working...